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Abstract
Objective: To evaluate the cost-effectiveness of post-diagnosis dementia treatment and coordination of care by memory
clinics compared to general practitioners’ care.
Methods: A multicentre randomised trial with 175 community dwelling patients newly diagnosed with mild to moderate
dementia, and their informal caregivers, with twelve months’ follow-up. Cost-effectiveness was evaluated from a societal
point of view and presented as incremental cost per quality adjusted life year. To establish cost-effectiveness, a cost-utility
analysis was conducted using utilities based on the EQ-5D. Uncertainty surrounding the incremental cost-effectiveness ratio
(difference in costs divided by difference in effects) was calculated by bootstrapping from the original data.
Results: Compared to general practitioners’ care, treatment by the memory clinics was on average J1024 (95% CI: 2J7723
to J5674) cheaper, and showed a non-significant decrease of 0.025 (95% CI:20.114 to 0.064) quality adjusted life years. The
incremental cost-effectiveness point estimate from the bootstrap simulation was J 41 442 per QALY lost if one would use
memory clinic care instead of general practitioner care.
Conclusion: No evidence was found that memory clinics were more cost-effective compared to general practitioners with
regard to post-diagnosis treatment and coordination of care of patients with dementia in the first year after diagnosis.
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Introduction
The quest for high quality, yet sustainable dementia care is
becoming ever more challenging. Dementia is an important – and
in numbers growing – cause of disability and burden of care and
one of the diseases with the largest per capita healthcare
consumption [1,2]. Moreover, there is a strong trend towards
early diagnosis in dementia, which may increase the period during
which care for patients with dementia will be asked for [3]. These
developments urge to answer the questions of how to optimise care
for this population and how to ensure this care for future
generations. Trying to answer these questions, several countries
have developed national dementia strategies [4,5,6,7,8]. Many of
these strategies focus on the nationwide availability of memory
clinics. Therefore, the number of memory clinics in different
countries increased rapidly over the last decades [9,10,11].
Memory clinics used to focus on diagnosing patients with
dementia. Today, memory clinics are also increasingly involved
in post-diagnosis treatment and care co-ordination of patients with
dementia [9]. There are data supporting the cost-effectiveness of
memory clinics as a diagnostic setting [12]. However, evidence
about memory clinics being cost-effective in post-diagnosis
treatment of dementia and follow-up care is scarce [13]. Knapp
and colleagues reviewed the literature on economic evaluations of
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dementia care [14]. They found that the majority of the economic
evidence was on pharmacological interventions. The non-phar-
macological interventions, on which they found little economic
evidence was often of poor quality and harder to interpret.
Recently we showed that there is no evidence of a difference in
effectiveness, evaluated as quality of life of the patient and
caregiver burden, between memory clinics and general practition-
ers with regard to dementia treatment and follow-up care [15].
While – on the basis of these results – effectiveness did not show a
significant difference, still performing an economic evaluation of
different guidance strategies is relevant, because there may be
differences in costs between the two treatment groups justifying
implementation of one strategy over the other. To our knowledge,
no studies comparing the cost-effectiveness of post-diagnosis
dementia treatment and care coordination by memory clinics
and general practitioners have been published. Therefore,
alongside the randomised trial of which the results of effectiveness
were published recently [15], we examined if post-diagnosis
treatment and coordination of care for patients with dementia and
their caregivers by memory clinics is cost saving and consequently
more cost-effective compared to care provided by general
practitioners.
Methods
Ethical Approval
The study was approved by the Medical Ethics Committee of
the Radboud University Nijmegen Medical Centre. Both each
patient and informal caregiver gave written informed consent
before inclusion in the study.
Study Design
This study (the AD-Euro Study), was a pragmatic multicentre
randomised trial with 12 months’ follow-up. Web based
randomisation took place after baseline measurements. Partici-
pants (patient-caregiver pairs) were assigned for post-diagnosis
dementia care to either the memory clinic or the general
practitioner. Details have been published elsewhere [15,16].
Participants
The whole study ran from December 2007 until July 2010, with
recruitment running from December 2007 until July 2009. Nine
Dutch memory clinics recruited participants for whom the
diagnostic work up resulted in a new diagnosis of dementia. Each
patient had an informal caregiver. Patient-caregiver pairs were
excluded when the patient lived in a nursing home, had a life
expectancy of less than a year, or needed specific memory clinic
care (for example, in the case of Creutzfeldt-Jakob disease) that
could not be given by general practitioners.
Intervention
The interventions consisted of care by either the memory clinic
or the general practitioner. The memory clinic provided treatment
and care coordination based on the specialist Dutch dementia
guideline of the Dutch Institute for Healthcare Improvement [17].
The main content of the intervention of the memory clinic was
prescribing and guidance of anti-dementia drugs (cholinesterase
inhibitors and memantine). Furthermore, they provided non-drug
interventions–for example day structure, referral to a nurse
specialist, day care, or home care. According to the guidelines,
both drug prescription/guidance and non-drug interventions were
delivered on a patient tailored basis. Patient-caregiver pairs
assigned to the general practitioner received post-diagnosis
treatment and care provided by the general practitioner based
on the Dutch general practice and homecare dementia guidelines
[18,19]. Most interventions available in memory clinic care are
also available in general practitioner care and were also delivered
on a tailored basis.
Measurements
After baseline measurements, follow-up measurements were
made at six and 12 months. Measurements were made at the
patients home by interview. Research assistants were instructed,
both oral and in writing, how to conduct the interview to prevent
differences between interviewers. An overview of the different
outcome measures and when they took place has been published
elsewhere [16].
Outcome measure. To establish cost-effectiveness, a cost-
utility analysis was conducted using utilities generated by the
EuroQol instrument (EQ-5D) for both patient and caregiver
[20,21,22]. We used the Dutch utility weight to calculate utilities
[23,24]. From the utility scores Quality Adjusted Life Years
(QALYs) were calculated as follows; {[(utility score at base-
line+utility score at 6 months)/2] x (6/12)}+{[(utility score at 6
months+utility score at 12 months)/2] x (6/12)}. QALYs of a
patient who died during the year of follow-up were given a utility
score of zero from their time of death onwards. Costs were
calculated from a societal perspective. The incremental cost-
effectiveness ratio (ICER) was calculated by dividing the difference
in costs by the difference in QALYs. As denominator, we used the
sum of the patients and caregiver QALY.
Costs
Costs were calculated by multiplying volumes of resources by
the cost price per resource unit (Table 1). Much of the information
about resources used was derived from the Case Report Form
(CRF) and was provided by the caregiver. Besides the CRF, we
used the hospital information system, the electronic medical record
of the general practitioners, and information from different health
care workers involved (e.g. physiotherapists, occupational thera-
pists, psychologists) to create the best possible estimate of resources
used. We based cost prices on the Dutch guidelines for economic
evaluation in healthcare [25], unless stated otherwise. All prices
were converted to the year 2009 by means of the consumer price
index [26] and expressed in Euros (at the time, J1 was equivalent
to British £ 0.85 and US $ 1.43). For a number of resources we
linearly interpolated the volume of resources used over the periods
between measurements, because no information was available for
every single week. The costs for productivity loss of the caregiver
were calculated based on the ‘‘friction cost method’’ [25]. The
hours of productivity loss were valued at an hourly wage of a
cleaning person [25]. With respect to informal care activities,
caregivers reported how time spent caring was allocated among
activities of daily living (ADLs) and instrumental activities of daily
living (IADLs). ADLs involved activities like e.g. dressing, eating,
walking, bathing, while IADLs involved more complicated
activities like e.g. shopping, providing medication, food prepara-
tion or housekeeping [27]. For the time spent on informal care we
used the sum of the hours spent on ADLs and IADLs. These hours
were valued at an hourly wage of a cleaning person [25].
Statistical Analysis
Data were analysed on an intention-to-treat basis. We used
descriptive statistics for baseline characteristics. To present
confidence intervals surrounding the costs and effects we
undertook nonparametric bootstrapping on the incremental costs
and effectiveness with 1000 draws from the original sample. The
incremental cost-effectiveness is represented visually by the
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incremental cost-effectiveness plane. The horizontal axis divides
the plane according to incremental effects, whereas the vertical
axis divides the plane according to incremental costs. The
probability that an intervention is cost-effective varies according
to the ceiling ratio. This probability is shown in the cost-
effectiveness acceptability curve (CEAC), based on nonparametric
bootstrapping [28]. We used Microsoft Office Excel 2007 and
SPSS 16.0.01 (release 16.0.2) to do the statistical analyses.
Results
We included 175 patient-caregiver pairs in the study; 87 were
randomly assigned to the memory clinic group and 88 to the
general practitioner group. Baseline characteristics of patients and
caregivers were similar between the two groups (Table 2). The
average age of the patients was 78.1 (SD 5.7) years, and caregivers
were on average 63.5 (SD 13.1) years old. The majority of the
caregivers (54%, n= 94) were partners, either married or living
together with the patient. Most of the patients (60%, n= 105) had
Alzheimer’s disease; in 84% (n= 147) of the patients, the severity
of the dementia was very mild to mild (clinical dementia rating 0.5
and 1). Cognition of the patients, measured with the mini-mental
state examination (range 0–30; higher score indicates better
cognition [29]) at baseline was on average 22.7 (SD 3.9).
Comorbidity of patients was measured with the cumulative illness
rating scale for geriatrics [30]. On average the baseline score was
about 9 (range 0–56; higher score indicates more comorbidity).
The utility score of the patient at baseline was 0.85 (SD 0.18) in
both groups. The utility score of the caregiver was 0.91 (SD 0.15)
in the memory clinic group and 0.88 (SD 0.15) in the general
practitioner group.
Outcome
We evaluated 160 pairs (77 in the general practitioner group
and 83 in the memory clinic group) out of the 175 patient-
caregiver pairs included in the study. Eleven pairs (four in the
memory clinic group) dropped out because they considered further
participation to be too burdensome. One caregiver died, one
caregiver did not fill out the questionnaires, and one caregiver was
not present during the measurements without giving any reasons,
all in the general practitioner group. In one patient in the general
practitioner group the diagnosis of dementia was changed just
after inclusion and was the reason for the patient and caregiver to
withdraw from the study.
The average cost, cumulated over 12 months follow-up, was
J22 035 (range J682 to J120 698) per patient in the memory
clinic group. In the general practitioner group the mean cost per
patient was J23 059 (range J674 to J78 721). This resulted in a
statistically not significant difference between the two study-groups
of J1024 (95% CI: 2J7723 to J5674). The analyses showed a
difference in QALYs of 0.025 in favour of the general practitioner
group, which was also not statistically significant (95% CI: 20.114
to 0.064). Including the minimisation factors as covariates in the
regression analysis left the difference in costs between the two
study-groups (J2441 (95% CI: 2J8152 to J3270)) and the
difference in QALYs (0.029 (95% CI: 20.1 to 0.06)) unchanged.
Also, adding comorbidity as covariate, left the difference between
the two study-groups unchanged (difference in costs J3470 (95%
CI 2J9257 to J2316) and in QALYs 0.015 (95% CI: 20.1 to
0.07)). From the different cost variables (Table 1) three variables
were significant different between the memory clinic and the
general practitioner group; the costs of hospital admissions
(p = 0.03), contact with the general practitioner (p = 0.03) and
contact with the memory clinic (p = 0.00).
The incremental cost-effectiveness point estimate from the
bootstrap simulation was J 41 442 per QALY lost if one would
use memory clinic care instead of general practitioner care. The
95% confidence interval surrounding the incremental cost-
effectiveness ratio (cost per QALY gained) in the bootstrap
simulation ranged from 2J1 221 001 (2.5 percentile) to J1 026
234 (97.5 percentile), using the percentile method. The scatter plot
in Figure 1 shows the visual representation of the result of the
bootstrap simulation. 59% of the bootstrapped ICERs is situated
below the horizontal axis (x-axis), meaning that the majority of the
ICERs indicate that the treatment in the memory clinic is cheaper
than for the general practitioner. Further, 66% of the simulations
is situated left from the vertical axis (y-axis), meaning that a
majority of the simulated ICERs indicate that the general
practitioner is more effective than the memory clinic. As a second
scenario we used the UK utility weights to calculate the
incremental cost-effectiveness ratio in a bootstrap simulation.
The results were similar to the results shown here and therefore
not shown.
The cost-effectiveness acceptability curve for the situation of our
primary cost-effectiveness analysis (ICERs numerator: all costs for
both patient and caregiver, denominator: the QALY’s of the
patients and their caregivers combined) is shown in Figure 2 by the
solid line. This figure indicates what would be an acceptable
amount of money to compensate the loss of a QALY if one would
Table 2. Baseline characteristics of the participants in the
Memory Clinic (MC) group and in the General Practitioner (GP)
group.
MC group (n =87) GP group (n =88)
Patient Caregiver Patient Caregiver
Number of participants
(n = 175)
87 87 88 88
Female, n (%) 54 (62%) 62 (71%) 52 (59%) 61 (69%)
Age, mean (sd)* 78.2 (6.2) 63.2 (13.4) 77.9 (5.2) 63.9 (12.9)
Type of dementia, n (%)
Alzheimer’s disease 53 (61%) 52 (59%)
Vascular dementia 9 (10%) 6 (7%)
Mixed/other 25 (29%) 30 (34%)
Severity of dementia, n
(%)
CDR 0,5 3 (3%) 5 (6%)
CDR 1 70 (81%) 69 (78%)
CDR 2 14 (16%) 14 (16%)
Relationship with
caregiver, n (%)
Partner 46 (53%) 48 (55%)
Child (in law) 36 (41%) 36 (41%)
Other 5 (6%) 4 (4%)
MMSE (sd) 22.7 (3.6) 22.7 (4.2)
CIRS G (sd) 9.2 (4.4) 8.8 (4.6)
EQ5D-utility (sd) 0.85 (0.18) 0.91 (0.15) 0.85 (0.17) 0.88 (0.15)
*standard deviation, CDR = clinical dementia rating scale (range 0–3; higher
score indicates more severe dementia);
CIRS G= cumulative illness rating scale for geriatrics (range 0–56; higher score
indicates more comorbidity); MMSE =mini-mental state examination (range 0–
30; higher score indicates better cognition).
doi:10.1371/journal.pone.0079797.t002
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choose memory clinic care over general practitioner care. For
example if a monetary compensation of J50 000 for one lost
QALY would be acceptable, then the probability of cost-
effectiveness is similar for both modalities (general practitioner
and memory clinic). If a smaller monetary value for a lost QALY is
acceptable, then the probability that the memory clinic is more
cost-effective increases to approximately 60%. In this last scenario
there will be no monetary compensation at all for a lost QALY.
Figure 2 also shows that the results are very much identical if we
used the QALY of the patient as rated by the caregiver instead of
the sum of the QALY of a patient-caregiver pair (dotted line).
Using only patients QALY and costs the probability that the
memory clinic is more cost-effective increases if a greater amount
of money than a monetary compensation of J50 000 for a QALY
gained would be acceptable. It can be noticed from Figure 2 that
all CEACs decrease as a function of the money value for a QALY
except the CEAC based on the patient alone.
Discussion
We found, applying a societal point of view, no evidence of a
statistical significant difference in cost-effectiveness between
memory clinics and general practitioners with regard to post-
diagnosis treatment and coordination of care for patients with
dementia at one year follow-up. A Bayesian interpretation of cost-
effectiveness (the CEAC) also shows that cost-effectiveness between
both modalities remains unresolved.
Comparison with other Studies
Comparison of our results with others is difficult, because of the
lack of similar studies. The study of Wolfs et al. showed that, in
comparison with usual care, an integrated multidisciplinary
diagnostic approach to dementia in a memory clinic setting
increased the health related quality of life of dementia patients and
was cost-effective [12]. Compared with our study, their patients’
cognition was worse and the patients had a much lower mean
quality adjusted life year value, which could be reasons why we
found relatively low costs in our study compared to the study by
Wolfs and colleagues.
Other studies compared cost of care of specific interventions –
which could be part of post diagnosis dementia guidance – with
alternatives [14]. Evidence for cost-effectiveness was seen for
certain pharmacological treatments and for some selected non-
pharmacological interventions. For example Graff and colleagues
found that occupational therapy for patients with dementia and
their caregivers was cost-effective compared with usual care [31].
However, cost-effectiveness data for the comparison between
general practitioner and memory clinic concerning post-diagnostic
care were not available.
Strengths and Limitations
We ensured a robust study design by using a randomised
controlled trial and we carried out the economic evaluation from a
societal perspective. By using a generic measure for quality of life
(EQ-5D) we are able to compare our results with other
interventions. This is important to interpret the cost savings for
a QALY lost. The participation of nine different memory clinics,
based in different settings (university hospital, general hospital, old
age psychiatry), enhanced the heterogeneity among care setting
and thus the generalisability of our study results. However,
differences in healthcare systems and variability in dementia care
between countries makes international generalisability of our
results difficult. Furthermore it is argued that, especially when
effects are expressed as QALYs in an economic evaluation, there is
a risk of double counting. We based QALYs on the EQ-5D where
productivity is no dimension. Therefore double counting seems
less of a threat than if quality of life was measured on for example
a VAS (Visual Analogue Scale), ranging from best to worst
Figure 1. Scatterplot of the estimated incremental costs and incremental effects obtained by bootstrap simulations.
doi:10.1371/journal.pone.0079797.g001
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imaginable quality of life. Further Krol et al. suggest that QALY
measures such as the EQ-5D are insensitive to concerns regarding
effects on income even when these are (explicitly) incorporated
[32].
Another limitation that possibly may have affected the outcome
of this study is the length of the follow-up period. Dementia is a
disease that progresses over years, so an extended follow-up lasting
several years would be preferable to the relatively short 12 month
period we used. It is known that costs increase over time in case of
a patient with dementia.
The lack of difference in costs was unanticipated due to the
assumption that primary care in general is cheaper. A possible
explanation could be that our group of patients was in their first
year after diagnosis with relatively mild dementia and therefore
often could take care of oneself with relatively little help from
others, both in the memory clinic and in the general practitioner
group. However, this is a very topical subject as there is a strong
international trend towards early diagnosis of dementia. Never-
theless, this means that these results cannot be generalised to more
severely affected individuals. With further progress of the disease
other needs will occur and it could be that in the long term a
difference between the memory clinic and the general practitioner
group could emerge.
Implications and Conclusions
This study adds important data, which seem to point to a lack of
difference in cost-effectiveness between memory clinics and
general practitioners in the treatment and coordination of care
for patients with dementia at one year follow-up. Together with
former results that no evidence was found of memory clinics being
more effective than general practitioners [15], these data are very
important for the ongoing debate on which type of post-diagnosis
treatment and follow-up care is best for which patients. The
development of dementia plans in many countries and the just
recently published report of the World Health Organisation has
once more stressed the need to continue to compare different
strategies of dementia care and to continue to increase the
evidence base [7,33,34]. If further studies verify our results, this
indicates that memory clinic guidance on average is not more
efficient than general practitioners in these early stages of
dementia. This is an important message, for both patients-
caregivers and policy makers, especially as one has to anticipate to
the trend of early diagnosis, and make the best choices for the
future. Under the scenario of lacking superiority of memory
clinics, both in terms of effectiveness and costs, other factors should
determine the most sustainable and efficient post-diagnosis
dementia care.
As our follow-up period was only one year after diagnosis, using
a decision analysis modelling strategy to compare costs and
effectiveness of the interventions in longer term should be a topic
for future research.
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Practitioner (solid line). The dotted line shows the curve if only the QALY of the patient as rated by the caregiver was used. The striped and the stripe-
dot line show the probability if the cost and QALY of the patient alone and if the cost and QALY of the caregiver alone (cost of the caregiver being
caregiving time and productivity loss) were used respectively.
doi:10.1371/journal.pone.0079797.g002
Cost-Effectiveness of Dementia Follow-Up Care
PLOS ONE | www.plosone.org 6 November 2013 | Volume 8 | Issue 11 | e79797
Author Contributions
Analyzed the data: EM RM EA. Wrote the paper: EM RM EA MOR.
Recruited the participants: GA GGW BdL FvR CSD DV FV MV CW
MOR. Approved the final manuscript: GA GGW BdL FvR CSD DV FV
MV CW MOR RM EA EM.
References
1. Jonsson L, Wimo A (2009) The cost of dementia in Europe: a review of the
evidence, and methodological considerations. Pharmacoeconomics., 27, 391–
403.
2. Wimo A, Winblad B, Jonsson L (2010) The worldwide societal costs of dementia:
Estimates for 2009. Alzheimers. Dement., 6, 98–103.
3. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, et al. (2012) Clinical
and biomarker changes in dominantly inherited Alzheimer’s disease. N. Engl. J.
Med., 367, 795–804.
4. Alzeimer Europe (2012) Available: http://www.alzheimer-europe.org/Policy-in-
Practice2/National-Dementia-Plans.Accessed 2013 Oct 11.
5. Burns A, Robert P (2009) The National Dementia strategy in England. BMJ,
338, b931.
6. Cahill S (2010) Developing a national dementia strategy for Ireland. Int. J.
Geriatr. Psychiatry, 25, 912–916.
7. Department of Health (2009) Living well with dementia: a National Dementia
Strategy. London: Department of Health website. Available: https://www.gov.
uk/government/publications/living-well-with-dementia-a-national-dementia-
strategy. Accessed 2013 Oct 11.
8. Eriksson S (2010) Developments in dementia strategy. Int. J. Geriatr. Psychiatry,
25, 885–886.
9. Jolley D, Benbow SM, Grizzell M (2006) Memory clinics. Postgrad. Med. J., 82,
199–206.
10. Passmore AP, Craig DA (2004) The future of memory clinics. Psychiatric
Bulletin, 28, 375–377.
11. Ramakers IH, Verhey FR (2011) Development of memory clinics in the
Netherlands: 1998 to 2009. Aging Ment. Health, 15, 34–39.
12. Wolfs CA, Dirksen CD, Kessels A, Severens JL, Verhey FR (2009) Economic
evaluation of an integrated diagnostic approach for psychogeriatric patients:
results of a randomized controlled trial. Arch. Gen. Psychiatry, 66, 313–323.
13. Melis RJ, Meeuwsen EJ, Parker SG, Olde Rikkert MGM (2009) Are memory
clinics effective? The odds are in favour of their benefit, but conclusive evidence
is not yet available. J. R. Soc. Med., 102, 456–457.
14. Knapp M, Iemmi V, Romeo R (2012) Dementia care costs and outcomes: a
systematic review. Int. J. Geriatr. Psychiatry, DOI: 10.1002/gps.3864.
15. Meeuwsen EJ, Melis RJ, Van Der Aa GCHM, Goluke-Willemse GAM, De
Leest BJM, et al. (2012) Effectiveness of dementia follow-up care by memory
clinics or general practitioners: randomised controlled trial. BMJ, 344, e3086.
16. Meeuwsen EJ, Melis RJ, Adang EM, Goluke-Willemse GA, Krabbe PF, et al.
(2009) Cost-effectiveness of post-diagnosis treatment in dementia coordinated by
Multidisciplinary Memory Clinics in comparison to treatment coordinated by
general practitioners: an example of a pragmatic trial. J. Nutr. Health Aging, 13,
242–248.
17. Richtlijn CBO (2005) Diagnostiek en medicamenteuze behandeling van
dementie Alphen aan den Rijn, (in Dutch).
18. Boomsma LJ, De Bont M, Engelsman C, Gussekloo J, Hartman C, et al. (2005)
Landelijke Eerstelijns Samenwerkings Afspraak Dementie. Huisarts Wet, 48,
124–126 (in Dutch).
19. Nederlands Huisartsen Genootschap (2003) NHG-Standaard Dementie M21 (in
Dutch).
20. Jonsson L, Andreasen N, Kilander L, Soininen H, Waldemar G, et al. (2006)
Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL.
Alzheimer Dis. Assoc. Disord., 20, 49–55.
21. Lamers LM, Stalmeier PF, McDonnell J, Krabbe PF, van Busschbach JJ (2005)
[Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff].
Ned. Tijdschr. Geneeskd., 149, 1574–1578.
22. Lamers LM, McDonnell J, Stalmeier PF, Krabbe PF, Busschbach JJ (2006) The
Dutch tariff: results and arguments for an effective design for national EQ-5D
valuation studies. Health Econ., 15, 1121–1132.
23. Dolan P (1997) Modeling valuations for EuroQol health states. Med. Care, 35,
1095–1108.
24. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL (2005)
Methods for the economic evaluation of health care programmes. (Third ed.)
Oxford University Press.
25. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FFH (2004)
Handleiding voor kostenonderzoek; Methoden en standaard kostprijzen voor
economische evaluaties in de gezondheidszorg. Geactualiseerde versie 2004
College voor zorgverzekeringen (CVZ) (in Dutch).
26. CBS (2009) Statistics Netherlands website. Available: http://statline.cbs.nl/
statweb/. Accessed 2013 Oct 11.
27. Wimo A, Nordberg G (2007) Validity and reliability of assessments of time.
Comparisons of direct observations and estimates of time by the use of the
resource utilization in dementia (RUD)-instrument. Arch. Gerontol. Geriatr.,
44, 71–81.
28. van Hout BA, Al MJ, Gordon GS, Rutten FF (1994) Costs, effects and C/E-
ratios alongside a clinical trial. Health Econ., 3, 309–319.
29. Folstein MF, Folstein SE, McHugh PR (1975) Mini-Mental State - Practical
Method for Grading Cognitive State of Patients for Clinician. Journal of
psychiatric research, 12, 189–198.
30. Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, et al. (1992) Rating
chronic medical illness burden in geropsychiatric practice and research:
application of the Cumulative Illness Rating Scale. Psychiatry Res., 41, 237–248.
31. Graff MJ, Adang EM, Vernooij-Dassen MJ, Dekker J, Jonsson L, et al. (2008)
Community occupational therapy for older patients with dementia and their
care givers: cost effectiveness study. BMJ, 336, 134–138.
32. Krol M, Brouwer W, Sendi P (2006) Productivity costs in health-state valuations
: does explicit instruction matter? Pharmacoeconomics 24, 401–414.
33. U.S.Department of Health and Human Services (2012) National Plan to address
Alzheimer’s disease - National Alzheimer’s Project Act (NAPA). Alzheimers.
Dement., 8, 234–236.
34. World Health Organization, Alzheimer’s Disease International (2012) Demen-
tia: a public health priority WHO press.
Cost-Effectiveness of Dementia Follow-Up Care
PLOS ONE | www.plosone.org 7 November 2013 | Volume 8 | Issue 11 | e79797
